Preferential Multi-Objective Bayesian Optimization for Drug Discovery
Tai Dang, Long-Hung Pham, Sang T. Truong, Ari Glenn, Wendy Nguyen, Edward A. Pham, Jeffrey S. Glenn, Sanmi Koyejo, Thang Luong · 2025
Read Preferential Multi-Objective Bayesian Optimization for Drug Discovery by Tai Dang, Long-Hung Pham, Sang T. Truong, Ari Glenn, Wendy Nguyen, Edward A. Pham, Jeffrey S. Glenn, Sanmi Koyejo, Thang Luong (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/arxiv-2503-16841.txt.
Introduction
Tai Dang and co-authors present a human-guided search method for drug discovery in a 2025 paper. Screening molecules by computer still leaves chemists to hand-pick a few hits, weighing many drug traits at once. That slow step bottlenecks the whole pipeline.
Their framework, CheapVS, lets chemists teach the search by picking winners from pairs of candidates. A Bayesian method learns those trade-offs and steers toward molecules the chemist would favor, while a docking model estimates how tightly each binds its target. Mixing human judgment with smart search could cut wasted synthesis and focus lab work on the most promising leads.
Catalog record
| CREATOR | Tai Dang, Long-Hung Pham, Sang T. Truong, Ari Glenn, Wendy Nguyen, Edward A. Pham, Jeffrey S. Glenn, Sanmi Koyejo, Thang Luong |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 63 KB |
| VERSION | 1.0 |
| LICENSE | http://creativecommons.org/licenses/by/4.0/ |
| RIGHTS | CC BY |
| SOURCE | arXiv |
Source: https://arxiv.org/abs/2503-16841
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Preferential Multi-Objective Bayesian Optimization for Drug Discovery Tai Dang, Long-Hung Pham, Sang T. Truong, Ari Glenn, Wendy Nguyen, Edward A. Pham, Jeffrey S. Glenn, Sanmi Koyejo, Thang Luong Abstract Despite decades of advancements in automated ligand screening, large-scale drug discovery remains resource-intensive and requires post-processing hit selection, a step where chemists manually select a few promising molecules based on their chemical intuition. This creates a major bottleneck in the virtual screening process for drug discovery, demanding experts to repeatedly balance complex trade-offs among drug properties across a vast pool of candidates. To improve the efficiency and reliability of this process, we propose a novel human-centered framework named CheapVS that allows chemists to guide the ligand selection process by providing preferences regarding the trade-offs between drug properties via pairwise comparison. Our framework combines preferential multi-objective Bayesian optimization with a docking model for measuring binding affinity to capture human chemical intuition for improving hit identification. Specifically, on a library of 100K chemical candidates targeting EGFR and DRD2, CheapVS outperforms state-of-the-art screening methods in identifying drugs within a limited computational budget. Notably, our method can recover up to 16/37 EGFR and 37/58 DRD2 known drugs while screening only 6% of the library, showcasing its potential to significantly advance drug discovery. † † affiliationnotice: Equal contribution 1 Introduction Figure 1 : Chemist-guided Active Preferential Virtual Screening performance in identifying EGFR and DRD2 drugs. The search is conducted on a 100K ligand library, screened for a maximum of 6% of the library. The plot compares different methods for structure-based binding affinity measurement (Vina, EDM-S, Chai-1) and objective types. The y-axis shows the percentage of the top number of approved drugs identified, while the x-axis represents the number of ligands screened. Multi-objective optimization (circles) across all methods for affinity measures outperforms affinity-only selection (triangles) and random screening (gray line). Error bars indicate 1 standard deviation. Virtual screening (VS) is a key pillar of modern computational drug discovery, acting as a rapid sift through massive molecular libraries-ranging from millions to billions of compounds-to identify a set of “hits” with promising therapeutic potential ( Shoichet, 2004 ; Lyu et al., 2023 ) . At the core of VS lies hit selection: the practical step in which a set of candidate compounds is manually chosen from top-ranked docking results, informed not only by binding affinity scores but also by key factors such as solubility, toxicity, and pharmacokinetic properties, all of which collectively determine a compound’s potential. Despite its centrality to drug discovery, VS and hit selection remain both resource-intensive. † † Code and data are at github.com/vietai/cheapvs . Traditional pipelines rely on exhaustive docking of the entire library, which demands substantial time and computational resources ( Lyu et al., 2019 ; Gorgulla et al., 2020 ) . Moreover, human expertise is required in the loop: medicinal chemists must examine the results to finalize which hits are worthy of costly experimental validation. In large-scale campaigns with millions of compounds, this process quickly becomes bottlenecked by both the computational costs and the limited bandwidth of experts. On top of the issue, vast computational resources are spent on characterizing unpromising (later-known low-scored) compounds, even though only a small fraction of top-ranked molecules typically move forward for hit selection and experimental validation. To address this problem, recent methods have combined active learning with binding affinity prediction to query compounds based on predicted binding affinity, substantially reducing computational overhead while maintaining high accuracy ( Graff et al., 2021 ; Zhou et al., 2024 ; Gentile et al., 2020 ) . Although binding molecules are good starting points for screening campaigns, the drug discovery process, in its entirety, is a complex multi-objective optimization problem. Indeed, VS presents a unique challenge due to its operation in a high-dimensional search space where these objectives (e.g., binding affinity, solubility, toxicity, pharmacokinetic properties, etc.) exhibit complex and often poorly understood interdependencies ( Hann and Keserü, 2012 ) . For instance, adding bulky functional groups can enhance binding affinity but simultaneously lower solubility or increase off-target toxicity, complicating the search for high-potential candidates. Balancing competing properties is key to robust drug leads. While single-objective active-learning approaches ( Graff et al., 2021 ; Gentile et al., 2020 ) have shown promise in efficiently identifying top-scored molecules from large-scale libraries, the screening process still overlooks important considerations that medicinal chemists weigh in real-world pipelines, such as synthetic accessibility, stability, toxicity, etc. Thus, much computational power is still wasted on molecules with poor profiles other than binding affinity. This disconnection also highlights the critical role of domain expertise, balancing multiple factors that purely physics-based methods often fail to capture. Unfortunately, while invaluable, the expert-driven hit selection process is labor-intensive when scaled to large candidate pools. To address these limitations, we present CheapVS (CHEmist-guided Active Preferential Virtual Screening) to assist chemists in expert-guided VS by leveraging a preferential multi-objective Bayesian optimization (BO) toolbox. By translating expert chemists’ nuanced understanding into multi-objective utility functions - incorporating factors such as binding affinity, solubility, or toxicity—our framework ensures that computational optimization captures subtle trade-offs that purely physics-based methods often overlook. This expert-guided approach refines the VS process, prioritizing candidates based on broader criteria crucial for downstream development. In doing so, we aim to make the hit identification process more efficient and aligned with expert preference and, ultimately, more effective in discovering promising drug leads from vast chemical spaces. Preference ranking relies on the availability of a good measurement of ligand properties. An important measurement is the binding affinity between the ligand and the target protein. Recent breakthroughs such as AlphaFold3 ( Abramson et al., 2024 ) and Chai-1 ( Boitreaud et al., 2024 ) have promised better measurement of binding affinity on a wide range of targeted proteins. Unfortunately, these methods are expensive, and the lack of understanding of their accuracy-efficiency trade-off has made it difficult for practitioners to select a suitable method for large scale VS. We compare the accuracy and efficiency of the physics-based and diffusion-based approaches, showing that while existing diffusion models are promising, their efficiency is far away from practical VS. Introducing a lightweight diffusion model, we significantly improve the efficiency of these tools while maintaining high performance, suggesting a path toward making deep learning models practical for VS. In summary, our key contributions are: • Eliciting Expert Preference for Efficient Virtual Screening: We optimize trade-offs among interdependent drug properties by leveraging chemists’ intuition through preference learning, translating domain knowledge into a latent utility function for more efficient VS. • Understanding Accuracy-Efficiency Trade-Off in Docking Models: We evaluate the accuracy-efficiency trade-off of the physics-based and diffusion-based approaches and use data augmentation to significantly improve the efficiency of the diffusion docking model. • Efficient Multi-Objective Virtual Screening: CheapVS considers various candidates’ properties to simultaneously optimize them, such as binding affinity and toxicity, moving beyond single-objective paradigms. 2 Related Work Efficient Decision Making in Virtual Screening VS ( Lionta et al., 2014 ; Kitchen et al., 2004 ) is a computational strategy for selecting promising molecules from large chemical libraries. Traditional high-throughput VS (HTVS) often employs computationally expensive structured-based binding affinity measurement methods ( McNutt et al., 2021 ; Koes et al., 2013 ; Eberhardt et al., 2021 ; Lyu et al., 2019 ) .